Research & Development
Ophirex’s lead candidate is oral varespladib for the treatment of snakebite envenomation in humans and dogs. Approval-enabling activities for the use of oral varespladib in humans are ongoing.
Additionally, Ophirex’s pipeline includes an intravenous formulation of varespladib, and an oral combination therapy pairing varespladib with a metalloproteinase inhibitor. A combination approach could provide oral, field-ready protection against two major classes of snake venom toxins: sPLA2s and SVMPs.
The Ophirex team and our research partners are dedicated to conducting all research in accordance with the highest ethical and moral standards for the humane treatment of animals. Ophirex follows best practices for animal research, including the three “Rs”: replacement (utilizing non-animal research methods when possible), reduction (limiting the number of animals in research) and refinement (utilizing research techniques that minimize pain and distress).